The companies specifically claim that Moderna uses their patented lipid nanoparticle (LNP) delivery technology, which is key to ensuring mRNA doesn’t degrade in the body, in its COVID-19 vaccine ...
March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle ... protecting their innovative LNP technology ...
Roivant Sciences (Nasdaq: ROIV) portfolio company Genevant Sciences and Canada’s Arbutus Biopharma (Nasdaq: ABUS) yesterday filed five international lawsuits seeking to enforce patents protecting ...
ABUS), have initiated international legal actions against Moderna (NASDAQ:MRNA), Inc., alleging infringement of patents related to their lipid nanoparticle (LNP) technology. The companies are seeking ...
March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid ... innovative LNP technology against Moderna, Inc ...
Genevant Sciences and Arbutus Biopharma have filed five international lawsuits against Moderna Inc. to enforce patents related to their lipid nanoparticle (LNP) technology, which is used in ...
March 03, 2025 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid ... innovative LNP technology against Moderna, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback